Searching for solutions to the skyrocketing cost of the EpiPen, lawmakers on the House Oversight Committee looked to Mylan chief executive officer Heather Bresch on Wednesday and asked why the pharmaceutical company could not lower the price for the drug delivery device used to treat life-threatening allergic reactions.
But as they blasted Bresch for the nearly 550 percent price increase since 2007, some saw the fix in a single word: competition. And with that suggestion, the U.S. Food and Drug Administration joined Mylan in the House committee’s crosshairs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
